TodayMonday, November 16, 2026

A 24-Basis-Point Cost Gap Puts Two Healthcare ETFs, XPH And PBE, On A Collision Course For Long-Term Investors

Expense ratios may seem like a minor detail, but over decades of compounding, a gap of 24 basis points can meaningfully separate two otherwise comparable funds.

That gap sits squarely between the State Street SPDR S&P Pharmaceuticals ETF (XPH) and the Invesco Biotechnology & Genome ETF (PBE), two healthcare-focused funds drawing growing attention from long-term portfolio builders.

XPH charges an annual expense ratio of just 0.35%, while PBE investors pay 0.59% per year for access to its more concentrated biotechnology strategy.

Beyond cost, the two funds pursue fundamentally different philosophies about where the best healthcare returns will originate over the coming years and decades.

XPH casts a wider net across the pharmaceutical sector, offering diversified exposure to a broad range of drug developers and established medicine companies.

PBE, by contrast, zeroes in on a concentrated slice of the healthcare universe, targeting biotechnology and genome-focused companies through a factor-based, momentum-driven approach.

That narrower focus has produced some eye-catching short-term numbers, with PBE posting a three-month total return of 11.3%, a figure that will appeal to investors comfortable with higher volatility.

Risk-adjusted metrics, however, tilt in XPH’s favor, as the fund carries a lower beta than PBE, meaning it has historically moved less aggressively relative to the broader market during periods of turbulence.

On the question of scale, the two funds are closely matched, with XPH holding approximately $447.70 million in assets under management against PBE’s $431.71 million.

XPH also holds an edge in one-year performance, a data point that complicates the narrative that PBE’s concentrated biotech bets necessarily translate into superior returns across longer measurement periods.

For investors who believe genomics and next-generation biotechnology will define the next era of medical innovation, PBE offers a direct and aggressive vehicle to capture that thesis.

Those with a preference for stability, cost efficiency, and diversified pharmaceutical exposure are more likely to find XPH a natural fit within a long-horizon portfolio strategy.

The decision ultimately comes down to an investor’s tolerance for sector concentration and short-term price swings versus a preference for steady, lower-cost healthcare sector participation.

For most long-term holders, the combination of broader diversification and a lower annual drag makes XPH the more straightforward fund to own through multiple market cycles.

Jordan Hayes

Jordan Hayes is a seasoned business reporter at iBusiness.News, specializing in market trends, corporate developments, and financial technology. With a keen eye for detail and a passion for breaking down complex business topics, Jordan delivers insightful coverage that keeps readers informed and ahead of the curve.

Before joining iBusiness.News, Jordan contributed to several financial publications, honing expertise in global markets and emerging industries.